Laparoseopic cholecystectomy for 58 end stage renal disease patients

被引:14
|
作者
Yeh, CN [1 ]
Chen, MF [1 ]
Jan, YY [1 ]
机构
[1] Chang Gung Univ, Chang Gung Mem Hosp, Dept Surg, Taoyuan, Taiwan
来源
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES | 2005年 / 19卷 / 07期
关键词
laparoscopic; cholecystectomy; endstage; renal disease;
D O I
10.1007/s00464-004-2207-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Since 1987, laparoscopic cholecystectomy (LC) has been widely used as the favored treatment for gallbladder lesions throughout the world. Because hemorrhage, infection, and delayed wound healing are the main causes of death after surgery for end-stage renal disease (ESRD), laparoscopic surgery is risky for ESRD patients. However, no information has been reported on such patients, so this study aimed to assess the safety of LC in ESRD patients. Method: From January 1994 to December 2003, the medical records of 58 ESRD patients under regular hernodialysis (HD) with gallbladder lesions undergoing LC were reviewed (ESRD-LC). The clinical features and outcomes of 6,182 patients with gallbladder lesions without ESRD undergoing LC were also summarized for comparison. Results: Of 6,240 patients with gallbladder lesions undergoing LC, 58 (0.93%) had ESRD with regular HD. The ESRD-LC group clearly exhibited older age, higher frequency of associated disease, lower hemoglobin and platelet count, and elevated alkaline phosphatase, blood urea nitrogen, and creatinine values. However, only a higher frequency of high American Society of Anesthesiologists (ASA) grade and elevated creatinine value could differentiate ESRD-LC and LC patients by multivariate analysis. Similar blood loss, conversion rate, morbidity, mortality, and hospital stay were noted for the two groups. Conclusions: LC is safe for ESRD patients with gallbladder lesions. Only a higher frequency of high ASA grade and elevated creatinine value could differentiate ESRD-LC and LC patients. Similar blood loss, conversion rate, morbidity, mortality, and hospital stay were achieved by applying LC to treat ESRD patients. However, appropriate preoperative preparations and experienced operative techniques are still required to prevent mortality.
引用
收藏
页码:915 / 918
页数:4
相关论文
共 50 条
  • [41] Uremic pericarditis, pericardial effusion, and constrictive pericarditis in end-stage renal disease: Insights and pathophysiology
    Rehman, Karim Abdur
    Betancor, Jorge
    Xu, Bo
    Kumar, Arnav
    Rivas, Carlos Godoy
    Sato, Kimi
    Wong, Leslie P.
    Asher, Craig R.
    Klein, Allan L.
    CLINICAL CARDIOLOGY, 2017, 40 (10) : 839 - 846
  • [42] Frequency of hypertensive response to dobutamine stress and diminished diagnostic value in patients with end-stage renal disease awaiting renal transplant
    Aftab, Waqas
    Motabar, Ali
    Pai, Ramdas G.
    Varadarajan, Padmini
    ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES, 2021, 38 (02): : 162 - 168
  • [43] Psychometric Properties of the Death Anxiety Scale-Extended among Patients with End-Stage Renal Disease
    Nia, Hamid Sharif
    Sharif, Saeed Pahlevan
    Koocher, Gerald P.
    Yaghoobzadeh, Ameneh
    Haghdoost, Ali Akbar
    Win, Ma Thin Mar
    Soleimani, Mohammad Ali
    OMEGA-JOURNAL OF DEATH AND DYING, 2020, 80 (03) : 380 - 396
  • [44] Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
    Kosoglou, Teddy
    Kraft, Walter K.
    Kumar, Bharath
    Statkevich, Paul
    Xuan, Fengjuan
    Ma, Lei
    Jennings, Lisa K.
    Schiller, James E.
    Langdon, Ronald B.
    Cutler, David L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (07) : 1049 - 1056
  • [45] Incidence of arrhythmias during dialysis in intensive-care-unit patients with end-stage renal disease
    Chelu, Mihail Gabriel
    Ibrahim, Yahya
    Shannoon, Farah
    Singh, Navneet
    Saeed, Mohammad
    Razavi, Mehdi
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 174 (03) : 753 - 754
  • [46] Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
    Teddy Kosoglou
    Walter K. Kraft
    Bharath Kumar
    Paul Statkevich
    Fengjuan Xuan
    Lei Ma
    Lisa K. Jennings
    James E. Schiller
    Ronald B. Langdon
    David L. Cutler
    European Journal of Clinical Pharmacology, 2012, 68 : 1049 - 1056
  • [47] CLINICAL DOCUMENTATION OF END-STAGE RENAL-DISEASE DUE TO HYPERTENSION
    SCHLESSINGER, SD
    TANKERSLEY, MR
    CURTIS, JJ
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (05) : 655 - 660
  • [48] SPECT MIBI imaging for cardiac output and index in end stage renal disease
    Coffey, John P.
    Woywodt, Alexander
    Hill, Jonathan C.
    HEMODIALYSIS INTERNATIONAL, 2011, 15 (03) : 320 - 325
  • [49] The role of myocardial perfusion SPECT in short-term cardiac prognosis of end-stage renal disease
    Ghaedian, Tahereh
    Kalhor, Leila
    Sadra, Hamideh
    Tehrani, Mohammadreza Hossein
    IRANIAN JOURNAL OF NUCLEAR MEDICINE, 2022, 30 (01): : 47 - 56
  • [50] Associations of parathyroid hormone levels and mineral parameters with heart rate variability in patients with end-stage renal disease
    Zhang, Lei
    Yang, Shaoyan
    Chen, Jianling
    Ma, Jinling
    Ren, Yueqin
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (06) : 1079 - 1085